Zobrazeno 1 - 10
of 4 081
pro vyhledávání: ''
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz
Autor:
Julie Lynch, Kristine E. Lynch, Christy Morrissey, Danil V. Makarov, Daniel J. Becker, Michael J. Kelley, Scott E. Sherman, Steve Y. Lee, Kyung Min Lee
Publikováno v:
JCO Precis Oncol
PURPOSEAdvances in precision oncology, including RAS testing to predict response to epidermal growth factor receptor monoclonal antibodies (EGFR mAbs) in colorectal cancer (CRC), can extend patients’ lives. We evaluated uptake and clinical use of K
Autor:
Steven Kao, Tessa A. Morris, Mark Voskoboynik, Benjamin Solomon, Luke McLean, Wasek Faisal, Ross Jennens, Sagun Parakh, Craig R. Lewis, Malinda Itchins, Adam R. Broad, Melvin Chin
Publikováno v:
JCO Precision Oncology. :561-568
PURPOSE Leptomeningeal disease (LMD) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma is associated with a poor prognosis and limited treatment options. Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor with
Autor:
Meena Thayu, A. Roshak, Jose Manuel Trigo, Jong Seok Lee, Keunchil Park, Santiago Viteri, Ramaswamy Govindan, Natasha B. Leighl, Ji-Youn Han, Paul Mitchell, Nahor Haddish-Berhane, James Chih-Hsin Yang, Chee Khoon Lee, Roland Elmar Knoblauch, Patricia Lorenzini, Byoung Chul Cho, Dawn Millington, Nicolas Girard, Alexander I. Spira, Tsung-Ying Yang, Rachel E. Sanborn, Eric B. Haura, J.C. Curtin, Matthew G Krebs, Pilar Garrido, Koichi Goto, Sang-We Kim, Dong Wan Kim, Karen L. Reckamp, Ki Hyeong Lee, Joshua Bauml, Joshua K. Sabari, Catherine A. Shu, John Xie
Publikováno v:
Park, K, Haura, E, Leighl, N B, Mitchell, P, Shu, C, Girard, N, Viteri, S, Han, J-Y, Kim, S-W, Lee, C K, Sabari, J, Spira, A, Yang, T-Y, Kim, D-W, Lee, K H, Sandborn, R, Trigo, J, Goto, K, Lee, J-S, Yang, J C-H, Govindan, R, Bauml, J M, Garrido, P, Krebs, M, Reckamp, K, Xie, J, Curtin, J, Haddish-Berhane, N, Roshak, A, Millington, D, Lorenzini, P, Thayu, M, Knoblauch, R & Cho, B C 2021, ' Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.21.00662
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with
Autor:
Xingyuan Xu, Mao Ye, Xiaoyu Zhang, Long-Yun Ye, Shanshan Li, Hang Shen, Qi Zhang, Tingbo Liang
Publikováno v:
Hepatology (Baltimore, Md.)
Background and aims Due to their inherent characteristics, the function of group-2 innate lymphoid cells (ILC2s) varies in a context-dependent manner. ILC2s are involved in certain liver diseases; however, their involvement in HCC is unknown. In the
Autor:
Michelangelo Fiorentino, Filippo Gustavo Dall'Olio, Rita Golfieri, Laura Marcolin, Benedetta Fragomeno, Giada Grilli, Giulia Manferrari, Andrea Ardizzoni, Francesca Sperandi, Mario Terracciano, Nastassja Tober, Francesco Gelsomino, Nicole Conci, Francesca Fontana, Andrea De Giglio, Stefano Brocchi
Publikováno v:
Clinical Lung Cancer. 22:423-431
Background: Circulating tumor cells (CTCs) are a promising source of biological information in cancer. Data correlating PD-L1 expression in CTCs with patients’ response to immune checkpoint inhibitors (ICIs) in non–small-cell lung cancer (NSCLC)
Autor:
Vernon K. Sondak, Andrew Poklepovic, Nikhil I. Khushalani, Jason J. Luke, Sunil Babu, Sigrun Hallmeyer, Zeynep Eroglu, Mario R. Velasco, Emily F. Higgs, Bruce Brockstein, Daniel J Olson, Thomas Krausz, Madhuri Bajaj, Timothy Carll, Riyue Bao, Jose Lutzky, Theodore Karrison, Brian W. Labadie, Thomas F. Gajewski, Yuanyuan Zha
Publikováno v:
J Clin Oncol
PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and p
Autor:
Tadayoshi Okimoto, Takahiro Hiratsuka, Shusaku Kurogi, Masafumi Inomata, Tomohisa Uchida, Daisuke Kakisako, Teijiro Hirashita, Masatsugu Moriyama, Chisato Nakada, Yoshiyuki Tsukamoto, Naoki Hijiya, Yuka Hirashita, Tsuyoshi Etoh, Tomonori Akagi, Masaaki Kodama, Yoshitake Ueda, Kazuhiro Mizukami, Yoko Kudo, Koichi Honda, Kazunari Murakami, Hidefumi Shiroshita
Publikováno v:
Laboratory Investigation. 101:1036-1047
Mutations in RAS or BRAF are associated with poor prognosis and resistance to epidermal growth factor receptor (EGFR)-targeted therapy in colorectal cancer (CRC). Despite their common ability to activate downstream genes such as MEK and ERK, the ther
Autor:
Mingming Yuan, Bei Wang, Rongrong Chen, Xuefeng Xia, Huang Chen, Dingrong Zhong, Jia Guo, Changxi Wang
Publikováno v:
Human Pathology. 114:90-98
Anaplastic lymphocyte kinase (ALK) rearrangement, a key oncogenic driver promoting the expression of ALK protein in tumor cells, is found in 2%-7% of patients with nonsmall cell lung cancer (NSCLC). ALK fusion is routinely determined with immunohisto
Autor:
Jurgen M.J. Piek, Phyllis van der Ploeg, Laura A.M. van Lieshout, Marjolein H.F.M. Lentjes-Beer, Ruud L.M. Bekkers, Steven L. Bosch, Anja van de Stolpe
Publikováno v:
Cellular Oncology (Dordrecht)
Cellular oncology, 44(4), 951-957. Springer
Cellular oncology, 44(4), 951-957. Springer
Purpose Anti-estrogen therapy may be used as a palliative treatment option in high-grade serous ovarian carcinomas (HGSC). However, clinical implementation is limited as the use of estrogen receptor (ER) protein expression by immunohistochemistry rem